𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Paclitaxel combined with fractionated radiation in vitro: A study with vulvar squamous cell carcinoma cell lines

✍ Scribed by Misa Raitanen; Virpi Rantanen; Jarmo Kulmala; Jaakko Pulkkinen; Pekka Klemi; Seija Grénman; Reidar Grénman

Publisher
John Wiley and Sons
Year
2001
Tongue
French
Weight
106 KB
Volume
97
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Concurrent paclitaxel and radiation has given promising results in the treatment of a variety of solid tumors. We wanted to test the efficacy of this combination for vulvar carcinoma, which currently has a poor outcome in advanced stages. The radiation sensitivity, sublethal damage repair (SLDR) capacity and effect of paclitaxel during fractionated radiation were assessed in our study on 7 vulvar inherently radioresistant squamous cell carcinoma (SCC) cell lines. The 96‐well plate clonogenic assay was used. Survival data were fitted to the linear quadratic model. The area under the curve (AUC), equivalent to mean inactivation dose (D̄), was obtained with numerical integration. AUC ratios between single‐dose radiation and fractionated radiation with or without paclitaxel were used to determine the SLDR of the cell lines and the effect of paclitaxel on it. Seven currently tested vulvar SCC cell lines were found to have a limited capacity of repairing sublethal damage (SLD). Only 3 of them presented SLDR of significance. The effect of concurrent radiation and paclitaxel was clearly additive when the radiation dose was fractionated in most of the cell lines. In addition, 2 of the cell lines having SLDR exhibited a trend toward losing the repair capacity when paclitaxel was present during the irradiation. In addition, the survival curve of the UM‐SCV‐1A cell line gave the impression of a true paclitaxel effect on SLDR. Paclitaxel used concurrently with fractionated radiation showed effectiveness on vulvar carcinoma. The effect was at least additive and could even be expected to abrogate the SLDR during split‐dose radiation. © 2001 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

In vitro concurrent paclitaxel and radia
In vitro concurrent paclitaxel and radiation of four vulvar squamous cell carcinoma cell lines
✍ Misa Jaakkola; Virpi Rantanen; Seija Grénman; Jarmo Kulmala; Reidar Grénman 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 550 KB

## BACKGROUND. The antitubule agent paclitaxel causes a cell cycle blockage in the most radiosensitive part of the cell cycle, the GJM phase. The possible radiosensitizing effect of paclitaxel was tested in four vulvar (UM-SCV-lA, UM-SCV-lB, UM-SCV-2, and UM-SCV-4) squamous cell carcinoma (SCC) ce

Supra-additive effect with concurrent pa
Supra-additive effect with concurrent paclitaxel and cisplatin in vulvar squamous cell carcinoma in vitro
✍ Misa Raitanen; Virpi Rantanen; Jarmo Kulmala; Hans Helenius; Reidar Grénman; Sei 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 106 KB

## Abstract The effect of concurrent paclitaxel and cisplatin was tested __in vitro__ in 5 vulvar squamous cell carcinoma (SCC) cell lines (UM‐SCV‐1A, ‐2, ‐4 and ‐7 and UT‐SCV‐3). Chemosensitivity was tested using the 96‐well plate clonogenic assay. Paclitaxel concentrations used varied between 0.4

Schedule-dependent radiation enhancement
Schedule-dependent radiation enhancement by paclitaxel with accelerated fractionated radiation in a human squamous carcinoma xenograft
✍ Marion A. Joschko; Lorraine K. Webster; Janice Groves; Kally Yuen; James F. Bish 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 661 KB

Paclitaxel is a microtubule inhibitor that blocks cells in G,M, the most radiosensitive phase of the cell cycle. Thus paclitaxel may be therapeutically useful in combination with radiation. The purpose of this study was to determine whether paclitaxel in different schedules could enhance radiation-i